Delivery of Respimat Soft Mist inhaler (SMI) from a Valved Holding Chamber (VHC)

V. Kushnarev (London, ON, Canada)

Source: International Congress 2017 – Inhalers and their use

Session: Inhalers and their use
Session type: Thematic Poster
Number: 3947

Disease area: Airway diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
V. Kushnarev (London, ON, Canada). Delivery of Respimat Soft Mist inhaler (SMI) from a Valved Holding Chamber (VHC). 3947

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Pressurized Metered Dose Inhaler (pMDI) Delivery to Infants via Valved Holding Chamber (VHC) with Facemask: Not All VHCs Perform the Same Source: International Congress 2017 – Inhalers and their use Year: 2017
Assessment of a ventilator circuit adapter to be used in conjunction with the Respimat* Soft Mist Inhaler (SMI) Source: International Congress 2017 – COPD and weaning Year: 2017
Pressurized Metered Dose Inhaler (pMDI) with holding chamber - Correct procedure Source: Procedure Video 2018 Year: 2018
Pressurized Metered Dose Inhaler (pMDI) - Correct procedure Source: Procedure Video 2018 Year: 2018
Efficacy in COPD patients of tiotropium administered via the Respimat® Soft MistÔ Inhaler (SMI) compared to HandiHaler® (HH) Source: Eur Respir J 2006; 28: Suppl. 50, 431s Year: 2006
Soft Mist Inhaler - Correct procedure Source: Procedure Video 2018 Year: 2018
Cost Effectiveness Comparison of a Dry Powder Inhaler to a Metered Dose Inhaler plus Valved Holding Chamber based on a Functional Respiratory Imaging (FRI) Model Source: Virtual Congress 2021 – Difficult decisions on expected outcomes: availability of hospital resources and improvement of treatment adherence Year: 2021
Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD Source: Eur Respir J 2013; 42: 606-615 Year: 2013
Cost Effectiveness Comparison of a Dry Powder Inhaler to a Metered Dose Inhaler plus Valved Holding Chamber based on an In-Vitro Drug Delivery Model Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more Year: 2020
Dose-response to tiotropium administered via the Respimat® Soft MistÔ Inhaler (SMI) to patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 318s Year: 2006
Valved holding chamber (VHC) angle can affect pressurized netered-dose inhaler (pMDI) medication delivery efficiency Source: International Congress 2018 – Determinants and monitoring of asthma control Year: 2018
COPD and asthma patients are satisfied with handling and inhalation characteristics of Soft Mist InhalerÔ (Berodual® Respimat®) Source: Eur Respir J 2006; 28: Suppl. 50, 739s Year: 2006
The in vitro fine particle dose with Symbicort Rapihaler pMDI is similar using either NebuChamber or AeroChamber Plus valved holding chamber spacer devices Source: Eur Respir J 2005; 26: Suppl. 49, 504s Year: 2005
Assessment of the suitability of filters for use in clinical studies with an HFA fluticasone propionate pressurized metered dose inhaler (pMDI) and a valved holding chamber (VHC) Source: Annual Congress 2011 - Lung function today and tomorrow II Year: 2011
In vitro comparison of aerosol characteristics of HFA albuterol (salbutamol) pressurized metered dose inhaler (pMDI) formulation from three valved holding chambers (VHCs) Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
The effect of inhalation duration on lung deposition with a pressurized metered-dose inhaler (pMDI) Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014
Valved holding chambers (VHCs) can have different medication delivery performance as a function of delay interval following actuation of the pressurized metered dose inhaler (pMDI) Source: International Congress 2014 – Respiratory symptoms in primary care populations Year: 2014
Device handling study of a novel breath-actuated inhaler Synchrobreathe vs pMDI Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies Year: 2019
In vitro lung deposition of fluticasone propionate/formoterol (FP/FORM) pressurized metered dose inhaler (pMDI) with different inhalation profiles Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014
Relative pulmonary bioavailability (BA) of fluticasone propionate/formoterol (FP/FORM) via pressurised metered-dose inhaler (pMDI) and a novel breath-triggered inhaler (BTI) Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017